Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
This report elaborates on the current development of the Cancer Angiogenesis Inhibitors industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
By Player:
Marsala Biotech
Levolta Pharmaceuticals
Hetero Drugs
ImClone Systems
Intas Pharmaceuticals
Five Prime Therapeutics
Kyowa Hakko Kirin
Mabtech
Novartis
Genentech
Fuji Film Kyowa Kirin Biologics
By Type:
Oncogene Targeted Therapy
Others
FGF Targeted Therapies
VEGF Targeted Therapy
Matrix Degrading & Remodeling Targeted Therapy
By Application:
Cancer
Interferon Alpha-2α
Ocular Neovascularization
By Research Region:
-
North China
-
Central China
-
South China
-
East China
-
Northeast China
-
Southwest China
-
Northwest China
TABLE OF CONTENT
Chapter 1 China Cancer Angiogenesis Inhibitors Market Overview 2018-2029
-
1.1 China Cancer Angiogenesis Inhibitors Industry Development Overview
-
1.2 China Cancer Angiogenesis Inhibitors Industry Development History
-
1.3 China Cancer Angiogenesis Inhibitors Industry Market Size (2018-2029)
-
1.4 China Cancer Angiogenesis Inhibitors Market Analysis by Type from Production Side
-
1.4.1 China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Oncogene Targeted Therapy (2018-2029)
-
1.4.2 China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
1.4.3 China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of FGF Targeted Therapies (2018-2029)
-
1.4.4 China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of VEGF Targeted Therapy (2018-2029)
-
1.4.5 China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Matrix Degrading & Remodeling Targeted Therapy (2018-2029)
-
1.5 China Cancer Angiogenesis Inhibitors Market Analysis by Application from Consumption End
-
1.5.1 China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Cancer (2018-2029)
-
1.5.2 China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Interferon Alpha-2α (2018-2029)
-
1.5.3 China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Ocular Neovascularization (2018-2029)
-
1.6 China Cancer Angiogenesis Inhibitors Market Analysis by Region
-
1.6.1 North China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.2 Central China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.3 South China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.4 East China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.5 Northeast China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.6 Southwest China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
1.6.7 Northwest China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
Chapter 2 China Cancer Angiogenesis Inhibitors Industry Development Environment
-
2.1 Industry Development Environment Analysis
-
2.1.1 Industry Technological Progress Analysis
-
2.1.2 Industrial Organizational Innovation Analysis
-
2.1.3 Changes in Social Habits
-
2.1.4 Alterations in Government Policies
-
2.1.5 Impact of Economic Globalization
-
2.2 Domestic and Foreign Industry Competition Analysis
-
2.2.1 Comparative Analysis on Cancer Angiogenesis Inhibitors Market Status and Competition at home and abroad in 2023
-
2.2.2 China Cancer Angiogenesis Inhibitors Market Status and Competition Analysis in 2023
-
2.2.3 China Cancer Angiogenesis Inhibitors Market Concentration Analysis in 2023
-
2.3 Problems and Countermeasures in the development of China Cancer Angiogenesis Inhibitors Industry
-
2.3.1 Industry Development Constraints
-
2.3.2 Industry Development Considerations
-
2.3.3 Suggestions on Industry Development Measures
-
2.3.4 Development Strategies for SMEs
-
2.4 Influence of COVID-19 Outbreak on Cancer Angiogenesis Inhibitors Industry Development
Chapter 3 Cancer Angiogenesis InhibitorsIndustry Chain Analysis
-
3.1 Cancer Angiogenesis Inhibitors Industry Chain
-
3.2 Cancer Angiogenesis Inhibitors Upstream Industry Analysis
-
3.2.1 Upstream Industry Development Status
-
3.2.2 Upstream Industry Development Forecast
-
3.2.3 Impact of Upstream Industry on the Cancer Angiogenesis Inhibitors Market
-
3.3 Cancer Angiogenesis Inhibitors Downstream Industry Analysis
-
3.3.1 Downstream Industry Development Status
-
3.3.2 Downstream Industry Development Forecast
-
3.3.3 Impact of Downstream Industry on the Cancer Angiogenesis Inhibitors Market
Chapter 4 China Cancer Angiogenesis Inhibitors Market, by Type
-
4.1 China Cancer Angiogenesis Inhibitors Market Trend, by Type
-
4.2 Product Types of Major Suppliers
-
4.3 Competitive Landscape of Major Types
-
4.4 China Cancer Angiogenesis Inhibitors Total Production Volume and Growth Rate from Production Side
-
4.5 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate, by Type
-
4.5.1 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Oncogene Targeted Therapy
-
4.5.2 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Others
-
4.5.3 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of FGF Targeted Therapies
-
4.5.4 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of VEGF Targeted Therapy
-
4.5.5 China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Matrix Degrading & Remodeling Targeted Therapy
Chapter 5 China Cancer Angiogenesis Inhibitors Market, by Application
-
5.1 Downstream Market Overview
-
5.2 Competitive Landscape of Major Applications
-
5.3 Market Potential Analysis, by Application
-
5.4 China Cancer Angiogenesis Inhibitors Total Market Size and Growth Rate from Consumption End
-
5.5 China Cancer Angiogenesis Inhibitors Market Size and Growth Rate, by Application
-
5.5.1 China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Cancer
-
5.5.2 China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Interferon Alpha-2α
-
5.5.3 China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Ocular Neovascularization
Chapter 6 China Cancer Angiogenesis Inhibitors Market, by Region
-
6.1 China Cancer Angiogenesis Inhibitors Production Volume and Production Value, by Region
-
6.2 China Cancer Angiogenesis Inhibitors Sales Volume and Sales Value, by Region
Chapter 7 North China Cancer Angiogenesis Inhibitors Market Analysis
-
7.1 North China Cancer Angiogenesis Inhibitors Market, by Type
-
7.2 North China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 8 Central China Cancer Angiogenesis Inhibitors Market Analysis
-
8.1 Central China Cancer Angiogenesis Inhibitors Market, by Type
-
8.2 Central China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 9 South China Cancer Angiogenesis Inhibitors Market Analysis
-
9.1 South China Cancer Angiogenesis Inhibitors Market, by Type
-
9.2 South China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 10 East China Cancer Angiogenesis Inhibitors Market Analysis
-
10.1 East China Cancer Angiogenesis Inhibitors Market, by Type
-
10.2 East China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 11 Northeast China Cancer Angiogenesis Inhibitors Market Analysis
-
11.1 Northeast China Cancer Angiogenesis Inhibitors Market, by Type
-
11.2 Northeast China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 12 Southwest China Cancer Angiogenesis Inhibitors Market Analysis
-
12.1 Southwest China Cancer Angiogenesis Inhibitors Market, by Type
-
12.2 Southwest China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 13 Northwest China Cancer Angiogenesis Inhibitors Market Analysis
-
13.1 Northwest China Cancer Angiogenesis Inhibitors Market, by Type
-
13.2 Northwest China Cancer Angiogenesis Inhibitors Market, by Application
Chapter 14 Company Profiles
-
14.1 Marsala Biotech
-
14.1.1 Marsala Biotech Company Profile
-
14.1.2 Marsala Biotech Cancer Angiogenesis Inhibitors Market Performance
-
14.1.3 Product&Service Introduction
-
14.2 Levolta Pharmaceuticals
-
14.2.1 Levolta Pharmaceuticals Company Profile
-
14.2.2 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Market Performance
-
14.2.3 Product&Service Introduction
-
14.3 Hetero Drugs
-
14.3.1 Hetero Drugs Company Profile
-
14.3.2 Hetero Drugs Cancer Angiogenesis Inhibitors Market Performance
-
14.3.3 Product&Service Introduction
-
14.4 ImClone Systems
-
14.4.1 ImClone Systems Company Profile
-
14.4.2 ImClone Systems Cancer Angiogenesis Inhibitors Market Performance
-
14.4.3 Product&Service Introduction
-
14.5 Intas Pharmaceuticals
-
14.5.1 Intas Pharmaceuticals Company Profile
-
14.5.2 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Market Performance
-
14.5.3 Product&Service Introduction
-
14.6 Five Prime Therapeutics
-
14.6.1 Five Prime Therapeutics Company Profile
-
14.6.2 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Market Performance
-
14.6.3 Product&Service Introduction
-
14.7 Kyowa Hakko Kirin
-
14.7.1 Kyowa Hakko Kirin Company Profile
-
14.7.2 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Market Performance
-
14.7.3 Product&Service Introduction
-
14.8 Mabtech
-
14.8.1 Mabtech Company Profile
-
14.8.2 Mabtech Cancer Angiogenesis Inhibitors Market Performance
-
14.8.3 Product&Service Introduction
-
14.9 Novartis
-
14.9.1 Novartis Company Profile
-
14.9.2 Novartis Cancer Angiogenesis Inhibitors Market Performance
-
14.9.3 Product&Service Introduction
-
14.10 Genentech
-
14.10.1 Genentech Company Profile
-
14.10.2 Genentech Cancer Angiogenesis Inhibitors Market Performance
-
14.10.3 Product&Service Introduction
-
14.11 Fuji Film Kyowa Kirin Biologics
-
14.11.1 Fuji Film Kyowa Kirin Biologics Company Profile
-
14.11.2 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Market Performance
-
14.11.3 Product&Service Introduction
Chapter 15 Research Conclusions and Investment Suggestions
-
15.1 Cancer Angiogenesis Inhibitors Industry Research Conclusions
-
15.2 Cancer Angiogenesis Inhibitors Industry Investment Suggestions
-
15.2.1 Suggestions on Industry Development Strategy
-
15.2.2 Suggestions on Industry Investment Direction
-
15.2.3 Suggestions on Industry Investment Strategy
List of Tables and Figures
-
Figure China Cancer Angiogenesis Inhibitors Industry Market Size (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Oncogene Targeted Therapy (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Others (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of FGF Targeted Therapies (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of VEGF Targeted Therapy (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume, Production Value and Growth Rate of Matrix Degrading & Remodeling Targeted Therapy (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Cancer (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Interferon Alpha-2α (2018-2029)
-
Figure China Cancer Angiogenesis Inhibitors Sales Volume, Sales Value and Growth Rate of Ocular Neovascularization (2018-2029)
-
Figure North China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure Central China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure South China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure East China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure Northeast China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure Southwest China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure Northwest China Cancer Angiogenesis Inhibitors Market Size and Growth Rate from 2018-2029
-
Figure Cancer Angiogenesis Inhibitors Industry Chain
-
Table Product Types of Major Suppliers in 2023
-
Figure China Cancer Angiogenesis Inhibitors Market Share by Type in 2018
-
Figure China Cancer Angiogenesis Inhibitors Market Share by Type in 2023
-
Figure China Cancer Angiogenesis Inhibitors Total Production Volume and Growth Rate from Production Side (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Oncogene Targeted Therapy (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Others (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of FGF Targeted Therapies (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of VEGF Targeted Therapy (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume and Growth Rate of Matrix Degrading & Remodeling Targeted Therapy (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Market Share by Application in 2018
-
Figure China Cancer Angiogenesis Inhibitors Market Share by Application in 2023
-
Figure China Cancer Angiogenesis Inhibitors Total Market Size and Growth Rate from Consumption End
-
Figure China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Cancer (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Interferon Alpha-2α (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Market Size and Growth Rate of Ocular Neovascularization (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Production Volume by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Production Volume Share by Region (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Volume Share by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Production Value by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Production Value Share by Region (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Production Value Share by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Sales Volume by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Sales Volume Share by Region (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Sales Volume Share by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Sales Value by Region (2018-2023)
-
Table China Cancer Angiogenesis Inhibitors Sales Value Share by Region (2018-2023)
-
Figure China Cancer Angiogenesis Inhibitors Sales Value Share by Region (2018-2023)
-
Table North China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table North China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure North China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table North China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table North China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure North China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table Central China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table Central China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure Central China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table Central China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table Central China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure Central China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table South China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table South China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure South China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table South China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table South China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure South China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table East China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table East China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure East China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table East China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table East China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure East China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table Northeast China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table Northeast China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure Northeast China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table Northeast China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table Northeast China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure Northeast China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table Southwest China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table Southwest China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure Southwest China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table Southwest China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table Southwest China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure Southwest China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table Northwest China Cancer Angiogenesis Inhibitors Production Volume by Type (2018-2023)
-
Table Northwest China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Figure Northwest China Cancer Angiogenesis Inhibitors Production Volume Share by Type (2018-2023)
-
Table Northwest China Cancer Angiogenesis Inhibitors Sales Volume by Application (2018-2023)
-
Table Northwest China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Figure Northwest China Cancer Angiogenesis Inhibitors Sales Volume Share by Application (2018-2023)
-
Table Marsala Biotech Company Profile
-
Table Marsala Biotech Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Levolta Pharmaceuticals Company Profile
-
Table Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Hetero Drugs Company Profile
-
Table Hetero Drugs Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table ImClone Systems Company Profile
-
Table ImClone Systems Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Intas Pharmaceuticals Company Profile
-
Table Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Five Prime Therapeutics Company Profile
-
Table Five Prime Therapeutics Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Kyowa Hakko Kirin Company Profile
-
Table Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Mabtech Company Profile
-
Table Mabtech Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Novartis Company Profile
-
Table Novartis Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Genentech Company Profile
-
Table Genentech Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
Table Fuji Film Kyowa Kirin Biologics Company Profile
-
Table Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Revenue, Price and Gross (2018-2023)
-
